NATRNasdaqPharmaceutical PreparationsFiscal year ends December 31
NATURES SUNSHINE PRODUCTS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$12.55−0.09 (-0.71%)
Close on Oct 19, 2026
- Market cap
- $230.13M
- P/E (TTM)
- 12.4
- Dividend yield
- –
NATURES SUNSHINE PRODUCTS INC revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asia | $221.78M | $207.79M | $201.25M | $186.29M | $176.86M | $138.72M | – | – | – | – | 46.2% | +6.7% |
| North America | $143.61M | $138.85M | $139.80M | $133.21M | $149.75M | $145.48M | – | – | – | – | 29.9% | +3.4% |
| Europe | $93.13M | $84.84M | $81.10M | $78.99M | $91.54M | $77.69M | – | – | – | – | 19.4% | +9.8% |
| Latin America and Other | $21.62M | $22.88M | $23.16M | $23.41M | $25.94M | $23.32M | – | – | – | – | 4.5% | -5.5% |
| Russia and Other Segment | – | – | – | – | $61.40M | $51.20M | – | – | – | – | – | – |
| Synergy WorldWide | – | – | – | – | – | – | – | $141.03M | $123.83M | $124.79M | – | – |
| NSP Americas | – | – | – | – | – | – | – | $156.12M | $166.02M | $175.92M | – | – |
| Europe | – | – | – | – | – | – | $62.52M | $56.31M | $32.19M | $30.00M | – | – |
| NSP China | – | – | – | – | – | – | – | $29.08M | $19.99M | $10.45M | – | – |
| Asia | – | – | – | – | – | – | $138.54M | $139.03M | – | – | – | – |
| Synergy WorldWide | – | – | – | – | – | – | $138.16M | $144.26M | – | – | – | – |
| Latin America and Other | – | – | – | – | – | – | $22.99M | $25.20M | – | – | – | – |
| Asia | – | – | – | – | – | $138.72M | $138.54M | – | – | – | – | – |
| Latin America and Other | – | – | – | – | – | $23.32M | $22.99M | – | – | – | – | – |
| North America | – | – | – | – | – | $145.48M | $138.16M | – | – | – | – | – |
| Europe | – | – | – | – | – | $77.69M | $62.52M | – | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asia | $40.16M | $34.11M | $30.55M | – | – | – | – | – | – | – | +17.8% |
| North America | $30.86M | $30.92M | $34.41M | – | – | – | – | – | – | – | -0.2% |
| Europe | $8.05M | $4.67M | $3.78M | – | – | – | – | – | – | – | +72.5% |
| Latin America and Other | $1.23M | $1.29M | $1.50M | – | – | – | – | – | – | – | -5.0% |
| Russia and Other Segment | – | – | – | – | $5.80M | $5.00M | – | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General health | $192.12M | $183.88M | $173.77M | – | – | – | – | – | – | – | 40.0% | +4.5% |
| Digestive | $124.37M | $111.74M | $103.87M | – | – | – | – | – | – | – | 25.9% | +11.3% |
| Cardiovascular | $81.64M | $81.70M | $83.59M | – | – | – | – | – | – | – | 17.0% | -0.1% |
| Immunity | $40.82M | $38.72M | $32.47M | – | – | – | – | – | – | – | 8.5% | +5.4% |
| Personal care | $23.27M | $17.80M | $18.30M | – | – | – | – | – | – | – | 4.8% | +30.7% |
| Weight management | $17.93M | $20.51M | $33.32M | – | – | – | – | – | – | – | 3.7% | -12.6% |
| Shipping and Handling | $2.50M | $2.10M | $1.40M | $1.20M | $1.70M | $3.40M | $6.20M | $7.10M | $8.20M | $9.20M | 0.5% | +19.0% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other | $172.57M | $160.56M | $204.48M | $195.64M | $221.61M | $188.19M | $163.64M | $158.93M | $149.15M | $135.46M | 35.9% | +7.5% |
| United States | $133.39M | $127.92M | $129.31M | $122.86M | $138.17M | $134.98M | $128.02M | $133.68M | $140.86M | $148.06M | 27.8% | +4.3% |
| Taiwan | $67.28M | $70.58M | $61.69M | $48.47M | $23.20M | – | – | – | – | – | 14.0% | -4.7% |
| Japan | $56.07M | $43.94M | – | – | – | – | – | – | – | – | 11.7% | +27.6% |
| South Korea | $50.84M | $51.36M | $49.85M | $54.94M | $61.11M | $62.04M | $70.56M | $72.21M | $52.02M | $57.64M | 10.6% | -1.0% |
From the segment and revenue-disaggregation notes of Natures Sunshine Products's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.